Synthetic molecules that can bind with high sequence specificity
to a chosen target in a gene sequence are of major interest in medicinal and biotechnological
contexts. These molecules show promise for the development of gene therapeutic agents,
diagnostic devices for genetic analysis, and as molecular tools for nucleic acid
manipulations.
Our experience in oligo chimera synthesis allows us to offer the synthesis of
a chimera at competitive prices and quick turnaround.
BSI offers synthesis of the following hybrid chimeric PNA products with the following
possible combinations:
|
Possible Combination
|
|
|
DNA
|
RNA
|
2'O-Me- RNA
|
2'-F-RNA
|
Constrained Nucleotide
|
PNA
|
Peptide
|
|
DNA
|
|
|
X
|
*
|
X
|
*
|
X
|
*
|
X
|
*
|
X
|
X
|
|
RNA
|
X
|
*
|
|
|
X
|
*
|
X
|
*
|
X
|
*
|
X
|
X
|
|
2'-O-Me- RNA
|
X
|
*
|
X
|
*
|
|
|
X
|
*
|
X
|
*
|
X
|
X
|
|
2'-F-RNA
|
X
|
*
|
X
|
*
|
X
|
*
|
|
|
X
|
*
|
X
|
X
|
|
Constrained Nucleotide
|
X
|
*
|
X
|
*
|
X
|
*
|
X
|
*
|
|
|
X
|
X
|
|
PNA
|
X
|
*
|
X
|
*
|
X
|
*
|
X
|
*
|
X
|
*
|
|
X
|
|
Peptide
|
X
|
*
|
X
|
*
|
X
|
*
|
X
|
*
|
X
|
*
|
X
|
|
*PO - phosphodiester; PS - phosphorothioate,
MPN - methylphosphonate
*Guarantee is for 20 mers
or longer. Shorter oligos may have fewer ODs.
Please refer to our large-scale services for
quantity >10 gram